Femara is associated with letrozole, an aromatase inhibitor that reduces the conversion of androgens to estrogen. By lowering circulating estrogen, letrozole can limit estrogen receptor stimulation in hormone-sensitive breast cancer.

Its established medical applications include treatment of certain estrogen-receptor-positive breast cancers, particularly in postmenopausal patients. Letrozole may be used in different stages of treatment according to individual clinical circumstances.

Aromatase inhibition can affect bone density, joints, cholesterol, and menopausal symptoms. The precise tablet strength and formulation should be confirmed from the product packaging.